SCHEMBL24252504

SCHEMBL24252504

Cc1nnc(N)c2ccc(-c3cc(B(O)O)ccc3OC(F)(F)F)cc12

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 8/20 0.36
SCN5A Q14524 2/20 0.36
ALOX5AP P20292 1/20 0.33
FEN1 P39748 1/20 0.33
LRRK2 Q5S007 1/20 0.32
RXRA P19793 2/20 0.31
KIT P10721 1/20 0.31
KDR P35968 1/20 0.31
FLT3 P36888 1/20 0.31
PLG P00747 1/20 0.31
F12 P00748 1/20 0.31
F11 P03951 1/20 0.31
KLKB1 P03952 1/20 0.31
PRSS1 P07477 1/20 0.31
PRSS2 P07478 1/20 0.31
PRSS3 P35030 1/20 0.31
ABL1 P00519 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30452320 1.00 SCN9A (0.36) SCN9ASCN5AALOX5APFEN1LRRK2
SCHEMBL24252269 0.86 DHFR (0.40) LRRK2PLGF12F11KLKB1
SCHEMBL24252712 0.85 SCN9A (0.32) SCN9APLGF12F11KLKB1
SCHEMBL24252277 0.83 TRPA1 (0.34) SCN9ASCN5AALOX5APFEN1PLG
SCHEMBL30453116 0.83 SCN9A (0.35) SCN9ASCN5AALOX5APFEN1ABL1
SCHEMBL24252657 0.83 SCN9A (0.35) SCN9ASCN5AALOX5APFEN1ABL1
SCHEMBL24252940 0.83 ALOX5AP (0.35) ALOX5APFEN1PLGF12F11
Formic Acid SCHEMBL25242412 0.82 DHFR (0.37) LRRK2PLGF12F11KLKB1
Formic Acid SCHEMBL30451288 0.82 DHFR (0.37) LRRK2PLGF12F11KLKB1
SCHEMBL24252506 0.82 MAP4K4 (0.37) KDRPLGF12F11KLKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON INC (US) 2026-03-12 US disclosed
US-12509474-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2025-12-30 US disclosed
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2024-04-04 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
EP-4185592-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF Annexon, Inc. (US) 2023-05-31 EP disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 SCN9A 3732/4885SCN5A 3532/4885ALOX5AP 246/4885
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 SCN9A 3732/4885SCN5A 3532/4885ALOX5AP 246/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 SCN9A 3732/4885SCN5A 3532/4885ALOX5AP 246/4885
US-12509474-B2 Inhibitors of complement factors and uses thereof SSB, UACA, CFH SCN9A 1089/4885SCN5A 482/4885ALOX5AP 351/4885
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFH, CFB, C5 SCN9A 601/4885SCN5A 301/4885ALOX5AP 167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.